ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,205.58
-2.54%
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs Yen
158.411
0.17%
Brent Oil
83.66
-0.81%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) ニュース

VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VNDA
日付受信時刻ニュースソース見出しコード企業名
2023/04/2807 : 00PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/04/2506 : 17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/04/2506 : 16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/2902 : 26PR Newswire (US)Vanda Prevails in Jet Lag Litigation Against the FDANASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1805 : 50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1720 : 06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1720 : 00PR Newswire (US)Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of DirectorsNASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1322 : 26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708 : 27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708 : 27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708 : 27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708 : 26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708 : 26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208 : 11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208 : 11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208 : 09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208 : 09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1506 : 41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1503 : 34Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1104 : 50Edgar (US Regulatory)Schedule 13g
(sc 13g)		NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1001 : 59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0922 : 24Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0906 : 10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0906 : 01PR Newswire (US)Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0208 : 30PR Newswire (US)Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/01/0623 : 00PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/2320 : 05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/1921 : 00PR Newswire (US)Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical StudyNASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/1704 : 54PR Newswire (US)Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launchNASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/1420 : 06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VNDA

最近閲覧した銘柄

AMEX
XLE
Energy Select Sector SPDR
COIN
SOLUSD
Solana
NYSE
MCD
McDonalds
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
NASDAQ
GOOGL
Alphabet
NYSE
NKE
Nike
SPI
SP500
S&P 500
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
NASDAQ
AMZN
Amazon.com
CCOM
SILVER
SILVER
USOTC
ADDYY
Adidas (QX)
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有